Monographie - Tacrolimus - Stabilis 4.0

Siste oppdatering :
27/01/2025

Immunosuppressiva

Tacrolimus

Mikstur

Injeksjon

Øyedråper

Stabilitet av farmasøytiske preparater

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Referanser

pdf

Kjemisk struktur

Mikstur

Referanser

Mikstur

Referanser : Tacrolimus

	Type	publikasjon
2436	Journal	Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of tacrolimus in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 1997 ; 54: 178-180.
2789	Journal	Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL. Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation 2006 ; 37, 8: 781-784.
3846	Journal	Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie 2016 71: 185?191.
3946	Journal	Friciu M, Zaraa S, Leclair G. Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes Can J Hosp Pharm 2017 ; 70,1 :51-53.
4177	Journal	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4673	Journal	Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V. Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases. Pharmaceutics 2022 ;14,1:118

Mentions Légales